Ask AI
ProCE Banner Activity

Answers in AL Amyloidosis Diagnosis and Treatment to Optimize Personalized Care

Clinical Thought

In this commentary, explore how a structured diagnostic approach and evolving therapeutic landscape are reshaping care for patients with AL amyloidosis, from early recognition to personalized treatment strategies in the relapsed setting. This commentary also summarizes key insights and actionable takeaways for healthcare professionals diagnosing patients with AL amyloidosis. 

Released: March 31, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Alexion Pharmaceuticals.

Alexion Pharmaceuticals

Target Audience

This educational activity is intended for hematologists and other healthcare professionals who care for patients with AL amyloidosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to recognize the early signs and symptoms of AL amyloidosis

  • Analyze the efficacy and safety profiles of novel therapies in AL amyloidosis management

  • Differentiate between treatment options for advanced or relapsed AL amyloidosis patients

  • Apply evidence-based strategies to manage treatment-related toxicities to optimize patient outcomes

  • Construct a comprehensive, multidisciplinary care approaches that enhance patient-centered care

Disclosure

Primary Author

Anita D'Souza, MD, MS: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Prothena; researcher: AbbVie, Alexion, Janssen, Prothena.

Jeffrey Zonder, MD: researcher: Bristol Myers Squibb, Janssen, RLL; consultant/advisor/speaker: Alexion, Prothena, Regeneron.